{"success":true,"data":{"pressRelease":{"id":"161882","rtpr_id":"nGNX2QdNWq-20261006","ticker":"DWTX","exchange":"NASDAQ","all_tickers":["DWTX"],"title":"Dogwood to Participate in the 2026 Maxim Growth Summit","author":"Globe Newswire","published_at":"2026-10-06T12:45:00.113Z","article_body":"ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq:\nDWTX) (the “Company”), a company that focuses on developing\nfirst-in-class, new non-opioid medicines to treat pain and neuropathy, today\nannounced that management will participate in the upcoming 2026 Maxim Growth\nSummit, taking place from October 12-14, 2026, in New York, NY. The conference\nbrings together industry leaders, innovators, and investors to explore the\nlatest trends and advancements across several industries.\n\nGreg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting\nwith institutional investors in one-on-one sessions and engaging with senior\nMaxim research analysts throughout the event. Dogwood recently announced the\ncompletion of enrollment in its Halneuron(®) Phase 2b Trial and anticipates\ntopline data readout of the study in November 2026.\n\nPortions of the event will also be streamed online at\nhttps://digital.maximgrp.com/. For registration information and a complete\nagenda of the Maxim Growth Summit, click here\n(https://www.globenewswire.com/Tracker?data=UnXSj9yaM9M5PwNZ_FDk5KB7Ug4HP3zSFV0QtK0Bgi4UXECdnVCU-qMUOctgASayTJihJpAJDy0_QhMGjkqgYrwIZbCF9lz6KoNiY87rJd8=).\n\nAbout Dogwood Therapeutics\n\nDogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical\ncompany focused on developing first-in-class, non-opioid medicines to treat\npain and neuropathic disorders. The Dogwood research pipeline includes two\nfirst-in-class development candidates, Halneuron(®) and SP16 IV.\n\nOur lead product candidate, Halneuron(®), is in Phase 2b development to treat\npain conditions including the neuropathic pain associated with chemotherapy\ntreatment. Halneuron(®) has been granted fast track designation from the FDA\nfor the treatment of CINP. Halneuron(®) is a non-opioid, Na(V) 1.7 analgesic\nwhich is a highly specific voltage-gated sodium channel modulator, a mechanism\nknown to be effective for reducing pain transmission. In clinical studies,\nHalneuron(®) treatment has demonstrated pain reduction in pain related to\ngeneral cancer and in pain related to chronic chemotherapy-induced neuropathic\npain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1\nagonist (“LRP1”) with potential to treat neuropathy and prevent or repair\nnerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in\nturn provides alpha-1-antitrypsin-like activity. Consistent with\nalpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16\npreclinically demonstrated anti-inflammatory (analgesic) action via potential\nreductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to\nrepair damaged tissue via increases in pAKT and pERK that regulate fundamental\nprocesses like growth, proliferation and survival. The forthcoming SP16 IV\nPhase 1b CIPN trial is fully funded by the National Cancer Institute.\n\nDogwood Therapeutics’ largest shareholder is a member of CK Life Sciences\nInt’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange\n(Stock code: 0775). For more information, please visit www.dwtx.com.\n\nForward-Looking Statements:\n\nStatements in this press release contain “forward-looking statements,”\nwithin the meaning of the U.S. Private Securities Litigation Reform Act of\n1995, that are subject to substantial risks and uncertainties. All statements,\nother than statements of historical fact, contained in this press release are\nforward-looking statements. Forward-looking statements contained in this press\nrelease may be identified by the use of words such as “anticipate,”\n“believe,” “contemplate,” “could,” “estimate,” “expect,”\n“intend,” “seek,” “may,” “might,” “plan,” “potential,”\n“predict,” “project,” “suggest,” “target,” “aim,”\n“should,” \"will,” “would,” or the negative of these words or other\nsimilar expressions, although not all forward-looking statements contain these\nwords. Forward-looking statements are based on Dogwood’s current\nexpectations and are subject to inherent uncertainties, risks and assumptions\nthat are difficult to predict, including risks related to the completion,\ntiming, enrollment, design and results of current and future clinical studies\nrelating to Dogwood’s product candidates; whether interim or final clinical\ndata will support continued development, regulatory submissions or approval;\nand Dogwood’s ability to finance its operations. Further, certain\nforward-looking statements are based on assumptions as to future events that\nmay not prove to be accurate. These and other risks and uncertainties are\ndescribed more fully in the section titled “Risk Factors” in the most\nrecently filed Annual Report on Form 10-K, which has been filed with the\nSecurities and Exchange Commission. Forward-looking statements contained in\nthis announcement are made as of this date, and Dogwood undertakes no duty to\nupdate such information except as required under applicable law.\n\nInvestor Relations:\n\nDan Ferry\nManaging Director\nLifeSci Advisors, LLC\ndaniel@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7fe5cc47-6599-477c-a858-0f0d9b9f7eb5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2QdNWq-20261006","title":"Dogwood to Participate in the 2026 Maxim Growth Summit","author":"Globe Newswire","ticker":"DWTX","created":"2026-10-06T12:45:00.113Z","tickers":["DWTX"],"exchange":"NASDAQ","article_body":"ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq:\nDWTX) (the “Company”), a company that focuses on developing\nfirst-in-class, new non-opioid medicines to treat pain and neuropathy, today\nannounced that management will participate in the upcoming 2026 Maxim Growth\nSummit, taking place from October 12-14, 2026, in New York, NY. The conference\nbrings together industry leaders, innovators, and investors to explore the\nlatest trends and advancements across several industries.\n\nGreg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting\nwith institutional investors in one-on-one sessions and engaging with senior\nMaxim research analysts throughout the event. Dogwood recently announced the\ncompletion of enrollment in its Halneuron(®) Phase 2b Trial and anticipates\ntopline data readout of the study in November 2026.\n\nPortions of the event will also be streamed online at\nhttps://digital.maximgrp.com/. For registration information and a complete\nagenda of the Maxim Growth Summit, click here\n(https://www.globenewswire.com/Tracker?data=UnXSj9yaM9M5PwNZ_FDk5KB7Ug4HP3zSFV0QtK0Bgi4UXECdnVCU-qMUOctgASayTJihJpAJDy0_QhMGjkqgYrwIZbCF9lz6KoNiY87rJd8=).\n\nAbout Dogwood Therapeutics\n\nDogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical\ncompany focused on developing first-in-class, non-opioid medicines to treat\npain and neuropathic disorders. The Dogwood research pipeline includes two\nfirst-in-class development candidates, Halneuron(®) and SP16 IV.\n\nOur lead product candidate, Halneuron(®), is in Phase 2b development to treat\npain conditions including the neuropathic pain associated with chemotherapy\ntreatment. Halneuron(®) has been granted fast track designation from the FDA\nfor the treatment of CINP. Halneuron(®) is a non-opioid, Na(V) 1.7 analgesic\nwhich is a highly specific voltage-gated sodium channel modulator, a mechanism\nknown to be effective for reducing pain transmission. In clinical studies,\nHalneuron(®) treatment has demonstrated pain reduction in pain related to\ngeneral cancer and in pain related to chronic chemotherapy-induced neuropathic\npain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1\nagonist (“LRP1”) with potential to treat neuropathy and prevent or repair\nnerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in\nturn provides alpha-1-antitrypsin-like activity. Consistent with\nalpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16\npreclinically demonstrated anti-inflammatory (analgesic) action via potential\nreductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to\nrepair damaged tissue via increases in pAKT and pERK that regulate fundamental\nprocesses like growth, proliferation and survival. The forthcoming SP16 IV\nPhase 1b CIPN trial is fully funded by the National Cancer Institute.\n\nDogwood Therapeutics’ largest shareholder is a member of CK Life Sciences\nInt’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange\n(Stock code: 0775). For more information, please visit www.dwtx.com.\n\nForward-Looking Statements:\n\nStatements in this press release contain “forward-looking statements,”\nwithin the meaning of the U.S. Private Securities Litigation Reform Act of\n1995, that are subject to substantial risks and uncertainties. All statements,\nother than statements of historical fact, contained in this press release are\nforward-looking statements. Forward-looking statements contained in this press\nrelease may be identified by the use of words such as “anticipate,”\n“believe,” “contemplate,” “could,” “estimate,” “expect,”\n“intend,” “seek,” “may,” “might,” “plan,” “potential,”\n“predict,” “project,” “suggest,” “target,” “aim,”\n“should,” \"will,” “would,” or the negative of these words or other\nsimilar expressions, although not all forward-looking statements contain these\nwords. Forward-looking statements are based on Dogwood’s current\nexpectations and are subject to inherent uncertainties, risks and assumptions\nthat are difficult to predict, including risks related to the completion,\ntiming, enrollment, design and results of current and future clinical studies\nrelating to Dogwood’s product candidates; whether interim or final clinical\ndata will support continued development, regulatory submissions or approval;\nand Dogwood’s ability to finance its operations. Further, certain\nforward-looking statements are based on assumptions as to future events that\nmay not prove to be accurate. These and other risks and uncertainties are\ndescribed more fully in the section titled “Risk Factors” in the most\nrecently filed Annual Report on Form 10-K, which has been filed with the\nSecurities and Exchange Commission. Forward-looking statements contained in\nthis announcement are made as of this date, and Dogwood undertakes no duty to\nupdate such information except as required under applicable law.\n\nInvestor Relations:\n\nDan Ferry\nManaging Director\nLifeSci Advisors, LLC\ndaniel@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7fe5cc47-6599-477c-a858-0f0d9b9f7eb5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T12:45:00.160648946Z","server_sent_at_ms":1791290700160},"received_at":"2026-10-06T12:45:00.212Z","source_url":null},"analysis":{"id":"150387","press_release_id":"161882","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Dogwood Therapeutics announced management will participate in the 2026 Maxim Growth Summit on October 12-14 in New York.\n\nCEO and Chairman Greg Duncan will hold one-on-one meetings with institutional investors and Maxim research analysts; portions of the event will be streamed online.\n\nThe company reiterated that its Halneuron Phase 2b trial completed enrollment with topline data expected in November 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance; watch for the Halneuron Phase 2b topline readout in November 2026."},"keyFigures":{"customDimensions":{"conference":"2026 Maxim Growth Summit, October 12-14, 2026","topline_data_timing":"November 2026"}},"namedEntities":{"people":[{"name":"Greg Duncan","role":"CEO and Chairman"},{"name":"Dan Ferry","role":"Investor Relations, Managing Director, LifeSci Advisors"}],"products":["Halneuron","SP16 IV"],"companies":[{"name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","relationship":"filer"},{"name":"Maxim Group","relationship":"conference host"},{"name":"CK Life Sciences Int'l., (Holdings) Inc.","relationship":"largest shareholder"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"National Cancer Institute","relationship":"funder of SP16 IV Phase 1b trial"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference participation announcement with no new financial, clinical, or regulatory data. The only notable item is a reiteration that Halneuron Phase 2b topline data is expected in November 2026."},"tickerRelevance":{"others":[{"ticker":"0775.HK","relevance":"largest shareholder (CK Life Sciences, Hong Kong-listed)"}],"primary":"DWTX"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-participation","issuerAuthored":true,"catalystMentioned":"Halneuron Phase 2b topline in November 2026"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Dogwood Therapeutics announced management will participate in the 2026 Maxim Growth Summit on October 12-14 in New York.\n\nCEO and Chairman Greg Duncan will hold one-on-one meetings with institutional investors and Maxim research analysts; portions of the event will be streamed online.\n\nThe company reiterated that its Halneuron Phase 2b trial completed enrollment with topline data expected in November 2026.","key_figures":{"customDimensions":{"conference":"2026 Maxim Growth Summit, October 12-14, 2026","topline_data_timing":"November 2026"}},"named_entities":{"people":[{"name":"Greg Duncan","role":"CEO and Chairman"},{"name":"Dan Ferry","role":"Investor Relations, Managing Director, LifeSci Advisors"}],"products":["Halneuron","SP16 IV"],"companies":[{"name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","relationship":"filer"},{"name":"Maxim Group","relationship":"conference host"},{"name":"CK Life Sciences Int'l., (Holdings) Inc.","relationship":"largest shareholder"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"National Cancer Institute","relationship":"funder of SP16 IV Phase 1b trial"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T12:45:04.580Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-participation","issuerAuthored":true,"catalystMentioned":"Halneuron Phase 2b topline in November 2026"}},"durationMs":4343,"modelName":"glm-5.3-flashx"}}